Sobieski Bancorp News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.05.18	Sobi™ Discloses Payments to Healthcare Professionals and Healthcare Organisations to Increase Transparency (PR Newswire)
21.05.18	Sobi Emphasises Commitment to Haemophilia Community at WFH 2018 World Congress (PR Newswire)
19.04.18	Invitation - Presentation of Sobi's Q1 2018 Results (PR Newswire)
03.04.18	Fredrik Wetterlundh Joins Sobi™ as Head of Human Resources (PR Newswire)
28.02.18	Sobi Launches Enhanced Corporate Sustainability Initiative (PR Newswire)
26.02.18	Henrik Stenqvist is Joining Sobi™ as New Chief Financial Officer (PR Newswire)
23.02.18	Kineret® (anakinra) Receives a Positive Opinion from CHMP for the Treatment of Still's Disease (PR Newswire)
13.02.18	Invitation - Presentation of Sobi's Q4/FY 2017 Results (PR Newswire)
07.02.18	Time to Elevate Protection in Haemophilia Care: New Data From Sobi™ (PR Newswire)
07.02.18	The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's™ Extended Half-life Therapies (PR Newswire)
23.01.18	FDA Accepts Investigational New Drug Application and Grants Fast Track Status for SOBI003 for the Treatment of MPS IIIA (PR Newswire)
04.01.18	Global Gas Insulated Substation Market to 2025 - Demand for More Reliable, Long Life Span and Less Maintenance Systems (PR Newswire)
16.11.17	Sobi™ - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease (PR Newswire)
27.10.17	The First Patient Enrolled in the ReITIrate Study Evaluating Immune Tolerance Induction With Elocta® (PR Newswire)
25.10.17	Sobi: Alprolix® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B (PR Newswire)
24.10.17	Sobi™ Establishes New Leadership Structure and Appoints Torbjörn Hallberg as General Counsel (PR Newswire)
06.10.17	Norbert Oppitz Joins Sobi™ as New Senior Vice President, Specialty Care (PR Newswire)
05.09.17	Sobi Receives Approval From the FDA for Once-daily Dosing Frequency of Orfadin® for the Treatment of HT-1 (PR Newswire)
06.07.17	Invitation - Presentation of Sobi's Q2 2017 Results (PR Newswire)
30.06.17	Xiapex® Gets Recommendation to be Made Available on National Health Service in England (PR Newswire)
27.06.17	EMA Approves the Potential to Dose Every 14 Days or Longer in Updated Dosing Regimen for Alprolix® (PR Newswire)
26.06.17	Elekta Chooses Brainlab to Distribute Stereotactic Neurosurgical Solutions Within Selected Markets in Europe (PR Newswire)
05.06.17	Sobi™ Keeps the Partner Products Business Area as an Integral Part of the Company (PR Newswire)
31.05.17	Sobi™ Discloses Payments to the Healthcare Professionals and Healthcare Organisations to Increase Transparency (PR Newswire)
18.05.17	Swedish Orphan Biovitrum AB - Elocta® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia A (PR Newswire)
17.05.17	Swedish Orphan Biovitrum AB - Orfadin® Capsules Approved in the Kingdom of Saudi Arabia for the Treatment of Hereditary Tyrosinemia Type 1 (PR Newswire)
03.05.17	Sobi Opens Office in Greece (PR Newswire)
13.04.17	Invitation - Presentation of Sobi's Q1 2017 Results (PR Newswire)
07.03.17	Swedish Orphan Biovitrum AB - FDA Approves in-use Storage at Room Temperature for Orfadin® Capsules (PR Newswire)
21.02.17	Sobi™ Enters Into new Distribution Agreement With Valeant for Ammonul® (PR Newswire)
03.02.17	Swedish Orphan Biovitrum AB - Invitation - Presentation of Sobi's Q4 and FY 2016 Results (PR Newswire)
02.02.17	Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy Alprolix in Children With Haemophilia B Published in The Lancet Haematology (PR Newswire)
02.02.17	Sobi Obtains Approval From the European Commission for new Dosing Frequency of Orfadin® (PR Newswire)
01.02.17	Sobi and Bioverativ to Reveal new Long-term Safety and Efficacy Data of Elocta® and Alprolix® at EAHAD (PR Newswire)
19.01.17	Swedish Orphan Biovitrum AB: First Patients Enrolled in 24 Month Real-world Study Evaluating Effectiveness of Elocta® (PR Newswire)
07.12.16	Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Sobieski Bancorp Inc Final Liquidation distribution

Aktien Top/Flop

Meistgelesene Nachrichten